Aarti Pharmalabs reports quarter ended June 30, 2026 results; approves Rs.149 Crores capex
Aarti Pharmalabs · Pharmaceuticals & Biotechnology
Key highlights
- Consolidated net profit Rs. 7,614.27 lakhs vs Rs. 4,603.09 lakhs a year earlier; standalone Rs. 7,130.66 lakhs vs Rs. 4,775.05 lakhs, for the quarter ended 30th June 2026.
- Rashesh C. Gogri to become Managing Director and Hetal Gogri Gala Executive Director from October 1, 2026, subject to shareholder approval at the ensuing AGM.
- Approved capacity addition of 405 Kl for the Intermediate Block at Rs. 149 Crores, within 1 year, financed by internal accruals & borrowings.
Why it's rated major development: the year-on-year change is 65% (50% or more)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Change in Directorate
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Aarti Pharmalabs
- Financial resultsMajor developmentAarti Pharmalabs approves Sept 2026 results; CFO Piyush Lakhani resigns
- Board / shareholder meeting outcomeNotableAarti Pharmalabs Limited announces results of 7th AGM held on September 22, 2026
- Capex / expansionMajor developmentAarti Pharmalabs Limited reports Q1 FY 2026-27 results and approves director role changes
- Financial resultsMajor developmentAarti Pharmalabs Ltd announces Q1 FY 2026-27 results and role changes in management
- Capex / expansionNotableAarti Pharmalabs inaugurates new manufacturing block at Tarapur to expand capacity
Other capex / expansion filings this fortnight
- Maharaja & Speedex India Limited raises manufacturing capacity to 72 lakh units/year
- Elin Electronics Q2 FY27 earnings report with 10% revenue growth and margin update
- HOAC Foods India Limited H1 FY27 Earnings Call Transcript dated November 5, 2026
- Gujarat State Fertilizers & Chemicals Limited Q2 FY27 Earnings Call Highlights
- Supriya Lifescience H1 revenue up 14.8% to ₹396.04 crore; Q2 profit falls
- V-MARC India Ltd announces Q2 & H1 FY27 unaudited financial results and review report
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.